<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231118060102N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-09-26</date_registration>
      <primary_sponsor>kharazmi University</primary_sponsor>
      <public_title>"Effect of adding pain neuroscience education to high-load strengthening exercises on clinical and functional outcomes of participants with hyper mobility spectrum disorder"</public_title>
      <acronym>Pain Neuroscience Education (PNE) ,Hyper mobility spectrum disorder (HSD)</acronym>
      <scientific_title>Comparison of the effect of adding pain neuroscience education to high-load strengthening exercises on clinical and functional outcomes of participants with hyper mobility spectrum disorder</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-11-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/79146</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: This was a single-blind (assessor-blinded), three-arm, parallel-group randomized controlled trial with a pre-test–post-test design. An a priori sample size calculation was performed using G*Power software for a repeated-measures ANOVA (group-by-time interaction as the effect of interest), assuming a medium effect size (Cohen’s f = 0.25), α = 0.05, 80% power, three groups and two measurement occasions. The required sample size was estimated at 42 participants; 45 participants (15 per group) were enrolled, Randomization description: Eligible participants were randomly allocated in a 1:1:1 ratio to one of three groups using numbers from 1 to 45 prepared in advance by the treating instructor and placed in sealed opaque envelopes in a box. The randomization sequence remained concealed until completion of each participant’s baseline assessment, at which point the corresponding envelope was opened. A project manager not involved in outcome assessment or treatment delivery oversaw allocation concealment, Blinding description: This was a single-blind (assessor-blinded) trial. The outcome assessor who performed all baseline and post-intervention assessments remained blinded to group allocation throughout the study. Participants and the treating instructor could not be blinded due to the nature of the interventions (exercise and education). Participants were instructed not to disclose their group assignment during follow-up testing.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Hypermobility spectrum disorder (HSD) with chronic shoulder symptoms / Shoulder hypermobility spectrum disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: high-threshold strengthening exercises with pain neuroscience training. Three familiarization sessions (two weeks) with training approaches to deal with pain and how to implement exercises will be held in approximately three months. The first session is a group session for a duration of 30 minutes to an hour with a maximum of six participants in each group using a PowerPoint. The second session, which includes three explanatory videos (online). The third session includes a 30-minute one-on-one conversation that relates the personal needs of the participants and the content to the pain neuroscience education. The contents of this group are about the physiology of pain and the nerve endings of pain. Intervention 2: Control group: Control group: The subjects of this group receive information on anatomy, physiology, the importance of self-care and ergonomic recommendations of Pasture. Intervention 3: Intervention group: High-threshold strength training: weight training for 16 weeks, training twice a week (individually supervised) in a fitness center, consisting of 60 minutes of training for the first session, 30 minutes for subsequent sessions, and once a week (unsupervised) is done in one's own home. Their training program includes five exercises for shoulder muscles. The exercise intensity model is progressive with decreasing patterns between increasing periods.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Pardis Garouee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iman Junubi St, 19 Alley, No. 158</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7185994343</zip>
        <telephone>+98 938 413 4786</telephone>
        <email>pgarouee@gmail.com</email>
        <affiliation>kharazmi University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Pardis Garouee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iman Junubi St,19 Alley, No. 158</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7185994343</zip>
        <telephone>+98 71 3632 7162</telephone>
        <email>pgarouee@gmail.com</email>
        <affiliation>Kharazmi University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women aged 18–65 years
Generalized joint hypermobility (GJH) defined by Beighton score:– ≥ 5 for women aged ≤ 50 years– ≥ 4 for women aged &gt; 50 years– or one point below the age-specific cutoff when the five-part questionnaire (5PQ) is positive (at least two positive items)
Presence of one or more of the following secondary symptomatic musculoskeletal manifestations:– Musculoskeletal pain in at least one shoulder for a minimum of three months– and/or recurrent atraumatic joint dislocation or joint instability involving at least two joints (including at least one shoulder), defined as any of the following:• At least three atraumatic dislocations of the same shoulder• At least two atraumatic dislocations in two different joints (including at least one shoulder) occurring at separate times• Medically confirmed joint instability in at least two joints (including at least one shoulder) not related to trauma</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Clinically suspected referred pain from the cervical spine
Systemic inflammatory rheumatic disease
Heritable connective tissue disorders (e.g., Marfan, Stickler, or Loeys–Dietz syndromes)
Neurological disorders
Pregnancy, childbirth within the previous 12 months, or plans to become pregnant during the study
Corticosteroid injection into the affected shoulder within the previous 3 months
Shoulder surgery within the previous 12 months
Inability to communicate verbally
Inability or unwillingness to comply with the study protocol or provide informed consent</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Other</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: high-threshold strengthening exercises with pain neuroscience training. Three familiarization sessions (two weeks) with training approaches to deal with pain and how to implement exercises will be held in approximately three months. The first session is a group session for a duration of 30 minutes to an hour with a maximum of six participants in each group using a PowerPoint. The second session, which includes three explanatory videos (online). The third session includes a 30-minute one-on-one conversation that relates the personal needs of the participants and the content to the pain neuroscience education. The contents of this group are about the physiology of pain and the nerve endings of pain.</i_keyword>
      <i_keyword>Control group: Control group: The subjects of this group receive information on anatomy, physiology, the importance of self-care and ergonomic recommendations of Pasture.</i_keyword>
      <i_keyword>Intervention group: High-threshold strength training: weight training for 16 weeks, training twice a week (individually supervised) in a fitness center, consisting of 60 minutes of training for the first session, 30 minutes for subsequent sessions, and once a week (unsupervised) is done in one's own home. Their training program includes five exercises for shoulder muscles. The exercise intensity model is progressive with decreasing patterns between increasing periods.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Shoulder-specific symptoms and functional disability. Timepoint: Baseline (before intervention) and immediately after the 16-week intervention. Method of measurement: Western Ontario Shoulder Instability Index questionnaire (21 items, total score ranging from 0 to 2100).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Shoulder pain intensity. Timepoint: Baseline (before intervention) and immediately after the 16-week intervention. Method of measurement: Numerical Pain Rating Scale (score range 0 to 10).</sec_outcome>
      <sec_outcome>Shoulder internal rotation muscle strength. Timepoint: Baseline (before intervention) and immediately after the 16-week intervention. Method of measurement: Hand-held dynamometer (force measured in kilograms).</sec_outcome>
      <sec_outcome>Shoulder external rotation muscle strength. Timepoint: Baseline (before intervention) and immediately after the 16-week intervention. Method of measurement: Hand-held dynamometer (force measured in kilograms).</sec_outcome>
      <sec_outcome>Shoulder internal rotation range of motion. Timepoint: Baseline (before intervention) and immediately after the 16-week intervention. Method of measurement: Universal goniometer (measured in degrees).</sec_outcome>
      <sec_outcome>Shoulder external rotation range of motion. Timepoint: Baseline (before intervention) and immediately after the 16-week intervention. Method of measurement: Universal goniometer (measured in degrees).</sec_outcome>
      <sec_outcome>Fear of movement. Timepoint: Baseline (before intervention) and immediately after the 16-week intervention. Method of measurement: Tampa Scale of Kinesiophobia-11 questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>No external funding (Kharazmi University provided academic facilities)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-09-20</approval_date>
        <contact_name>Ethics Committee of the Research Institute of Physical Education and Sport Sciences</contact_name>
        <contact_address>3, 5th Alley, Mirem ad Street, Motahari Street, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
